Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 7
Submit an article Journal homepage
179
Views
4
CrossRef citations to date
0
Altmetric
Letter to the Editor

A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma

Jianliang YangDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Yuankai ShiDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, ChinaCorrespondence[email protected] [email protected]
,
Xiaohui HeDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Mei DongDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Changgong ZhangDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Peng LiuDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Shengyu ZhouDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Yan QinDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Lin GuiDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
,
Sheng YangDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
&
Yan SunDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
 show all
Pages 2218-2221 | Received 24 May 2014, Accepted 09 Dec 2014, Published online: 11 Feb 2015

References

  • Sun J, Yang QP, Lu ZH, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol 2012; 138:429–434.
  • Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 2011;6:77.
  • Abouyabis AN, Shenoy PJ, Lechowicz MJ, et al. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008;49:2099–2107.
  • Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural Killer/T-cell lymphoma. J Clin Oncol 2006;24:181–189.
  • You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004;15:618–625.
  • Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351–2356.
  • Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100:366–375.
  • Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834–1839.
  • Yong W, Zheng W, Zhu J, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009;88:647–652.
  • Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410–4416.
  • Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 2013;119: 348–355.
  • Lin N, Song Y, Zheng W, et al. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol 2013;6:44.
  • Ahn HK, Kim SJ, Hwang DW, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Invest New Drugs 2013;31:469–472.
  • Dong M, He XH, Liu P, et al. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol 2013;30:351.
  • Li L, Zhang C, Zhang L, et al. Efficacy of apegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma. Neoplasma 2014;61:225–232.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.